Aillis key facts
as of Oct 2026- Developer of an artificial intelligence-equipped pharyngoscopy system designed to diagnose infectious diseases from pharyngeal photographs.
- Aillis is valued at approximately $125.2M as of Oct 2026 (last reported valuation).
- It has raised $54.6M; the latest was Later Stage VC ($13.4M) in Apr 2025.
- Notable investors include J-Startup, Nissay Capital, Z Venture Capital, Pegasus Tech Ventures, Mirai Creation Capital — 27 tracked in total.
- Status: Privately Held (backing).
Aillis's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·The complete investor list: 27 names
- ·Watch Aillis: the Monday email on marks, rounds and moves
Aillis funding rounds
No funding rounds for Aillis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Aillis
27+Aillis valuation
Aillis's last reported valuation was $125 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
Aillis investors
27 investors are on record for Aillis, including J-Startup, Nissay Capital, Z Venture Capital and Pegasus Tech Ventures. By type, the record holds 5 venture capital firms.
About Aillis
Developer of an artificial intelligence-equipped pharyngoscopy system designed to diagnose infectious diseases from pharyngeal photographs. The company's platform utilizes a specialized camera to capture images of the pharynx and applies AI technology to analyze the images for signs of infection, enabling healthcare providers to diagnose illnesses efficiently and accurately.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2017
- Employees
- 100
- Website
- aillis.jp/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.